Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the month of July 2021, with a specific reporting date of July 23, 2021. The document serves as a report of a foreign private issuer regarding corporate governance updates rather than a financial performance report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is exclusively focused on board committee changes and contains no financial data.
Material Changes
The material change reported is an update to the Board Committee membership effective July 23, 2021:
- Dr. Anne Beal has been appointed as a member of the Audit & Risk Committee.
- This appointment is in addition to her existing membership on the Corporate Responsibility Committee.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The scope is limited to the administrative announcement of the board appointment.
Key Facts for Investor Verification
- Dr. Anne Beal's new role on the Audit & Risk Committee is effective as of July 23, 2021.
- Dr. Anne Beal retains her position on the Corporate Responsibility Committee.
- The filing contains no financial performance data for the period.